PriceTargets.com logo

NASDAQ:SAVA - Cassava Sciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.33
  • Forecasted Upside: -60.20 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$48.58 As of 02/26/2021 01:00 AM ET
▼ -2.3 (-4.52%)
1 month | 3 months | 12 months
Get New Cassava Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SAVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SAVA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$19.33
▼ -60.20% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Cassava Sciences in the last 3 months. The average price target is $19.33, with a high forecast of $24.00 and a low forecast of $14.00. The average price target represents a -60.20% upside from the last price of $48.58.
Buy
The current consensus among 3 contributing investment analysts is to buy stock in Cassava Sciences.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/3/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/1/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/22/2020Cantor FitzgeraldInitiated CoverageOverweight$24.00High
i
Rating by C. Duncan at Cantor Fitzgerald
9/23/2020HC WainwrightUpgradeNeutral ➝ Buy$20.00Medium
i
Rating by V. Bernardino at HC Wainwright
9/14/2020Maxim GroupUpgradeHold ➝ Buy$14.00High
i
Rating by Jason McCarthy at Maxim Group
6/7/2020Maxim GroupReiterated RatingHoldLow
i
Rating by Jason McCarthy at Maxim Group
5/18/2020HC WainwrightDowngradeBuy ➝ NeutralHigh
i
Rating by V. Bernardino at HC Wainwright
5/15/2020Maxim GroupDowngradeBuy ➝ HoldN/A
i
Rating by Jason McCarthy at Maxim Group
5/8/2020HC WainwrightReiterated RatingBuy$6.00 ➝ $16.00High
i
Rating by Vernon Bernardino at HC Wainwright
3/26/2020Maxim GroupInitiated CoverageBuy$12.00Medium
i
Rating by Jason McCarthy at Maxim Group
1/10/2020Maxim GroupBoost Price TargetBuy$3.00 ➝ $12.00Low
i
Rating by Jason McCarthy at Maxim Group
12/6/2019HC WainwrightReiterated RatingPositive ➝ Buy$3.00 ➝ $6.00High
i
Rating by Vernon Bernardino at HC Wainwright
11/13/2019HC WainwrightReiterated RatingBuy$3.00Medium
i
Rating by Vernon Bernardino at HC Wainwright
9/18/2019Maxim GroupReiterated RatingBuy$3.00Low
i
Rating by Jason McCarthy at Maxim Group
9/13/2019HC WainwrightSet Price TargetBuy$3.00Low
i
Rating by Vernon Bernardino at HC Wainwright
9/10/2019Maxim GroupReiterated RatingBuy$3.00High
i
Rating by Jason McCarthy at Maxim Group
8/16/2019HC WainwrightReiterated RatingBuy$3.00Low
i
Rating by V. Bernardino at HC Wainwright
8/13/2019Maxim GroupReiterated RatingBuy$3.00Low
i
Rating by Jason McCarthy at Maxim Group
8/1/2019HC WainwrightInitiated CoverageBuy$3.00 ➝ $3.00High
i
Rating by V. Bernardino at HC Wainwright
6/25/2019Maxim GroupInitiated CoverageBuy$3.00High
i
7/17/2017GabelliDowngradeHold ➝ SellLow
i
Rating by K. Kedra at Gabelli
9/13/2016GabelliDowngradeBuy ➝ Hold$17.50N/A
i
Rating by K. Kedra at Gabelli
(Data available from 2/27/2016 forward)
Cassava Sciences logo
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.
Read More

Today's Range

Now: $48.58
$47.79
$52.00

50 Day Range

MA: $32.36
$8.18
$87.95

52 Week Range

Now: $48.58
$1.63
$117.54

Volume

2,258,952 shs

Average Volume

10,247,938 shs

Market Capitalization

$1.24 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47

Frequently Asked Questions

What sell-side analysts currently cover shares of Cassava Sciences?

The following Wall Street analysts have issued research reports on Cassava Sciences in the last year: Cantor Fitzgerald, HC Wainwright, Maxim Group, and Zacks Investment Research.
View the latest analyst ratings for SAVA.

What is the current price target for Cassava Sciences?

3 Wall Street analysts have set twelve-month price targets for Cassava Sciences in the last year. Their average twelve-month price target is $19.33, suggesting a possible downside of 60.2%. Cantor Fitzgerald has the highest price target set, predicting SAVA will reach $24.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $14.00 for Cassava Sciences in the next year.
View the latest price targets for SAVA.

What is the current consensus analyst rating for Cassava Sciences?

Cassava Sciences currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SAVA will outperform the market and that investors should add to their positions of Cassava Sciences.
View the latest ratings for SAVA.

What other companies compete with Cassava Sciences?

Other companies that are similar to Cassava Sciences include Arena Pharmaceuticals, Eidos Therapeutics, ChemoCentryx, FibroGen, Sage Therapeutics, I-Mab, Hutchison China MediTech, Reata Pharmaceuticals, Nektar Therapeutics, PTC Therapeutics, Arvinas, Hypera, Apellis Pharmaceuticals, Insmed and Legend Biotech.

How do I contact Cassava Sciences' investor relations team?

Cassava Sciences' physical mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The company's listed phone number is 512-501-2444 and its investor relations email address is [email protected] The official website for Cassava Sciences is www.cassavasciences.com.